Reported about 8 hours ago
Incyte Corp.'s stock fell sharply after the results of a third-phase clinical trial for its drug Povorcitinib, aimed at treating chronic skin diseases, did not meet investor expectations, showing less effectiveness than prior trials. Despite the disappointing data, the company plans to continue seeking regulatory approval, citing the drug's potential value.
Source: YAHOO